Plenaxis Related Published Studies
Well-designed clinical trials related to Plenaxis (Abarelix)
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. [2002.04]
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. [2001.11]
Other research related to Plenaxis (Abarelix)
Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. [2006.12]
Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. [2006.10]
Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. [2004.10]
Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. [2004.05]
Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. [2004.02]
An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. [2003.11]
Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. [2003.05]
Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. [2003.04]
The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. [2001.05]
Technology evaluation: Abarelix, Praecis pharmaceuticals. [2000.10]
Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. [2000.09]
Other possibly related research studies
Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer. [2005.04]
Innovations in antineoplastic therapy. [2005.03]
Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. [2004.09]
Hormonal therapy of prostate cancer. [2002.08]
Luteinizing hormone-releasing hormone antagonists in prostate cancer. [2001.08]
Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. [2003.12.22]
Gateways to clinical trials. [2003.11]
Gateways to clinical trials. [2002.11]
Gateways to Clinical Trials. June 2002. [2002.06]
Gateways to clinical trials. [2002.05]
Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. [2002.04]
Development of GnRH antagonists for prostate cancer: new approaches to treatment. [2000]
Proprietary Rel-Ease drug delivery technology: opportunity for sustained delivery of peptides, proteins and small molecules. [2006.09]
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. [2006.08]
Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer. [2006.03]
Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. [2006.01]
Hormone ablation therapy: lightening the load for today's prostate cancer patient. [2007.02]
|
